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The role of estrogens in Alzheimer’s disease (AD) involvingβ-amyloid (Aβ) generation and plaque formationwas mostlytested in
ovariectomized mice withor withoutAPP mutations.The aim ofthe present study was to explore the abnormalitiesofneural cells
in a novel mouse model of AD with chronic estrogen deﬁciency. These chimeric mice exhibit a total FSH-R knockout (FORKO)
and carry two transgenes, one expressing the β-amyloid precursor protein (APPsw, Swedish mutation) and the other expressing
presenilin-1lackingexon9(PS1Δ9).Themostprominentchangesinthecerebral cortex andhippocampus ofthesehypoestrogenic
mice were marked hypertrophy of both cortical neurons and astrocytes and an increased number of activated microglia. There
were no signiﬁcant diﬀerences in the number of Aβ plaques although they appeared less compacted and larger than those in
APPsw/PS1Δ9 control mice. Similar glia abnormalities were obtained in wild-type primary cortical neural cultures treated with
letrozole, an aromataseinhibitor. The concordance of results from APPsw/PS1Δ9 mice with or without FSH-R deletion and those
withletrozoletreatment invitro(withandwithoutAβtreatment) ofprimarycortical/hippocampalcultures suggeststheusefulness
of these models to explore molecular mechanisms involved in microglia and astrocyte activation in hypoestrogenic states in the
central nervous system.
1.Introduction
In the brain, estradiol is formed in neurons and a subpop-
ulation of astrocytes by aromatase-mediated conversion of
precursor androgens [1]. Estrogen deﬁciency was reported
to accelerate β-amyloid (Aβ) plaque formation in an Al-
zheimer’s disease (AD) mouse model combining an aro-
matase deﬁciency and an APP23 transgene [2]. There was
no signiﬁcant diﬀerence between the estrogen levels in
APP23 and wild-type mice independent of age (3, 6, and
12 months); however, the estrogen levels in the brains of
APP23-aromatase knockout mice were signiﬁcantly reduced
compared to age-matched ovariectomized APP23 mice.
Furthermore, microglial cultures prepared from the brains
o ft h e s eA P P 2 3m i c es h o w e di m p a i r e dA β clearance and/or
degradation [2].
Another model of estrogen imbalance was provided by
follicule-stimulating hormone receptor (FSHR) knockout
(FORKO)mice [3]. Ourearlierstudiesshowed that homozy-
gous females were infertile, whereas males exhibited reduced
fertility [4]. Similarly, inactivating mutations in the FSHR
gene in women cause absolute infertility and amenorrhea2 Journal of Aging Research
[5]. Young and aged FORKO mice exhibit several biochem-
ical and morphological abnormalities in the CNS, including
mislocalization of chaperones and mitogenactivated kinases,
and hypertrophy of astrocytes, especially in aged mice [6–8].
These mice also develop metabolic syndrome [9]a n dc a r -
diovascular abnormalities, which are risk factors for AD and
otherneurodegenerativedisorders[10–13]. Althoughseveral
studies indicated the contribution of reduced estrogens in
circulation to the AD pathology, the role of this peripheral
estrogen pool is still disputed [14–17]. The role of the local
(brain) deﬁcit of neuroestrogens is considered to be a critical
player leading to CNS impairment associated with mild
cognitive impairment (MCI) and AD in women [18–20].
Diﬀerent studies suggest estrogens as anti-inﬂammatory
agents [21, 22] and powerful modulators of glial cells [23,
24]. Depending on their activation states, microglia exhibit
both neuroprotective (weakly activated) [25–27]a n dd e -
structive(hyperactivated)roles[28–31].Theirroleininﬂam-
matory processes may aﬀect AD development [32, 33]. In-
deed, epidemiological studies reported that the use of non-
steroidal anti-inﬂammatory drugs could reduce the risk of
AD [22, 34, 35]. However, activated resident microglia in a
hypoestrogenic environment were unable to eﬀectively clear
Aβ deposits and possibly contributed to Aβ oligomerization
[2, 36]. Although the internalization of Aβ is not limited
to microglia, as both astrocytes and neurons are capable of
uptake, microglia are the most eﬃc i e n ta tt h i sp r o c e s si n
addition to retaining the capacity to degrade Aβ [37].
Several mouse models overexpressing human amyloid
precursor protein (APP) with and without mutations were
generated[38].Thesemicedevelopedamyloidplaquesindif-
ferentnumbers, usuallynotbefore6–9monthsofage.Mouse
models expressing APPsw (Swedish mutation) did not de-
velop extensive amyloid aggregation before 18 months of
age[39,40].However,doubletransgenic mice APPsw/PS1Δ9
(presenillin-1 lacking exon 9) exhibited elevated Aβ-levels at
6 months of age and extensive extracellular Aβ-deposits in
the cortex and hippocampus at 9–12 months [40].
The objective of this study was to examine the impact of
chronic hormone imbalance due to FSHR gene inactivation
in the above APPsw/PS1Δ9 mouse model on the develop-
mentofcorticaland hippocampalplaquepathologyandglial
cell morphology. Accordingly, FSHR knockout (FORKO)
micewithtargeteddisruptionoftheFSHRgene[3]werebred
with the APPsw/PS1Δ9l i n e .I nA P P s w / P S 1 Δ9a n dF O R K O -
APPsw/PS1Δ9mice,plaquesappearedasearlyas3monthsof
age. Although their number did not diﬀer signiﬁcantly from
the APPsw/PS1Δ9 mice later in life, FORKO-APPsw/PS1Δ9
mice exhibited signiﬁcantly larger and more diﬀuse plaques
in cortical and hippocampal regions. Moreover, enhance-
ment of glial cell recruitment, size, and activation was seen
as early as 3 months of age, as revealed by immunohisto-
chemical labeling for both astrocytes and microglia. We
further show that treatment of wild-type hippocampal pri-
mary cultures with the aromatase inhibitor, letrozole, also
leads to glial cell hypertrophy and activation, suggesting that
early changes in microglia and astrocytes may contribute to
the progression of AD under conditions of local estrogen
deﬁciency.
2.Materialsand Methods
2.1. MouseStrains. FORKO (Fshr−/−) males were produced
by interbreeding 129T2/SVEmsJ Fshr+/− males and females
[3, 4] and were then crossed with double transgenic females
(C3HeJ x C57BL/6J F1 hybrid background). The two trans-
genes,APPsw andPS1Δ9,werepreviouslydescribed[39–41].
Both are expressed under the control of the mouse prion
protein (PrP) promoter and are thus highly expressed in
brain neuronsand astrocytes. Theywere obtained by replace-
ment of the PrP open reading frame and their structure is
summarized in Figure 1 and its legend. F1 mice (Fshr+/−)
were intercrossed. F2 Fshr+/+ mice were intercrossed, while
Fshr−/− males were crossed with Fshr+/− females (Fshr−/−
females are sterile). Only the male or the two females of each
breeding were positive for the 2 transgenes. F3 mice positive
for the two transgenes and either Fshr+/+ (1 out of 4) or
Fshr−/− (1 out of 8) were analyzed. They were derived from
3a n d4d i ﬀerent breedings, respectively.
2.2. Genotyping. Genomic DNAfrom the tails of 3-week-old
mice was extracted and tested by PCR ampliﬁcation for the
presence of the two transgenes, APPsw and PS1Δ9, and the
genotype at the Fshr locus. The wild-type PrP gene and
APPsw transgene were detected simultaneously using two
speciﬁc sense primers, 5 -AACCTCATGGTGGTAGTTGG
and 5 GATCTCTGAAGTGAATCTGGATG, respectively,
and a common antisense primer, 5 -GCAAGAATGAGA-
ACCACCTC. The combination of the 3 primers generated
645 and 420bp products corresponding to the PrP wild-type
allele (internal control) and APPsw transgene, respectively.
Similarly, 3 primers were used to detect the wild-type PrP
gene and the PS1D9 transgene. Two speciﬁc sense primers,
5 -AGCAACCAGAACAACTTCGT and 5 -GTTGCAGAG-
AATGATGATGG, and acommonreverseprimer, 5 -AGCA-
AAGAGCAACTGGTCTACT, generated 450 and 568bp
products for the PrP gene and PS1Δ9 transgene, respectively.
Finally, wild-type Fshr+/+ alleles were detected using the
sense 5 -AGTTCAATGGCGTTCCG and antisense 5 -
CATGTCAGTAGTACATTAGAG primers (634bp product)
while the Fshr−/− alleles were detected using neomycin-
speciﬁc primers, sense 5 -AAGGGACTGGCTGCTATTG
and antisense 5 -AGAAAAGCGGCCATTTTC, to generate a
348bp product.
2.3. Immunohistochemistry. Female mice were sacriﬁced at 3
or6monthsandbrainsweredissected.Onehalfofeachbrain
w a sf r o z e ni ni s o p e n t a n ea t−35◦Ca n dk e p ta t−80◦C. A
second half was ﬁxed by immersion in 4% formaldehyde for
24hrs, embedded in paraﬃn and sectioned into 5μmt h i c k
sections. Cryosections (10μm), obtained from the frozen
half-brains, were ﬁxed in 4% paraformaldehyde for 1hr,
washed in PBS, and incubated with rabbit antibodies
directed against GFAP (AB5804; Chemicon International,
Temecula, Calif, USA) or Iba1 (Wako Chemicals USA, Rich-
mond, Va, USA) at 1:400 and 1:200 dilutions in 10% goat
normal serum in PBS, respectively. GFAP labeling was re-
vealed using the ImmunoCruz staining system (Santa Cruz,Journal of Aging Research 3
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Figure 1: Generation of chimeric mice. A construct used to gen-
erate chimeric mice expressing human APP with Swedish mutation
andhypoestrogenism due to the absence ofFSH receptor. A murine
prion protein (PrP) genomic fragment was modiﬁed to obtain the
vector phgPrP [21]. A region containing 6kb of promoter, exon 1
(noncoding), intron 1, and exon 2 (non-coding) was fused to the
third and last exon (2008bp) and 2.2kb of downstream sequence.
The subsequent removal of the PrP open reading frame (ORF)
generated the vector MoPrP.Xho, in which the cDNA encoding
PS1 lacking the exon 9 (amino acids 290–319) was subcloned [44].
Finally, the region encoding residues 592 to 622 from the mouse
APP-695 cDNA was substituted by the corresponding human one
(hatched area), which contains the Swedish KM to NL double
mutation and the Aβ42 coding sequence. The resulting hybrid
mouse/human cDNA was subcloned in MoPrP.Xho [11]. Half
arrows indicate the position of the primers used for genotyping
the mice. For complete inactivation of the FSH receptor gene, a
638bp fragment containing part of the 5  untranslated region, the
coding region of exon 1 (101bp), and about 129bp of intron 1 was
substituted by a 1.7kb neomycin expression cassette (dotted box)
[19]. A multiplex PCR using primers indicated by half arrows was
used to genotype the oﬀspring [16]. Black boxes: non-coding PrP
e x o n s1a n d2 ;g r e yb o x :c o d i n ge x o n ;O R Fa r eb o x e d .
Calif, USA), while the Iba1 labeling was revealed by an
Alexa 555 secondary antibody (A-21422; Molecular Probes,
Invitrogen) used at a 1:100 dilution in 10% goat normal
serum in PBS for 30min at room temperature. ForAβ detec-
tion, the paraﬃn sections were deparaﬃnized by xylene,
rehydratedbysuccessiveincubationsin100%to50%ethanol
solutions and PBS. Incubations were performed overnight
at 4◦C with rabbit antibodies, which are directed against
the 8 ﬁrst residues of Aβ40 (FCA18, a generous gift from F.
Checler, Institute of Molecular and Cellular Pharmacology,
Valbonne, France) or the C-terminal part of either Aβ1-40
(A8326 from Sigma, Mississauga, ON, Canada) or Aβ1-42
(66481Gfrom BDBiosciences, SanJose, Calif, USA),all used
at a 1:300 dilution in 10% goat normal serum in PBS. After
3 washes in PBS, the antibodies were revealed by using the
Histomouse kit (Zymed Laboratories, San Francisco, CA,
USA).Tovisualizesenileplaques,sectionswereincubatedfor
1hr in 1% aqueous thioﬂavin S (ThS; Sigma), dehydrated
in 70% ethanol, cleared with Entellan new rapid mounting
mediumformicroscopy(EMScienceHarleco),andobserved
under UV light.
2.4. Image Analysis for Plaques and Glia Quantiﬁcation. Im-
munostained sections were analyzed by means of an Olym-
pus BX51 microscope, equipped with motorized stage and
focus coupled by means of a CCD camera to a MCID Elite
Image analysis system (Imaging Research Inc. St. Catherine,
ON, Canada) according to the procedure described by Bell
et al. [42, 43]. In summary, the total number of pixels in
one ﬁeld was taken as 1.0, and all immunoﬂuorescent pixels
from GFAP or Iba1 staining were taken as % of the total.
Photomicrophotographs were collected from four to six
sections per animal (n = 5–7 per experimental group).
The use of preset shape was not desirable as plaques are
not always symmetrical or uniform in size. To maintain
consistency and determine plaque size, the outer border
of the plaque was traced by the same individual. Plaque
sizes were determined as perimeters or total surfaces, and
mean values ± SD were calculated for all plaques within
the same size range for the selected brain structures in both
genotypes.
2.5. Primary Hippocampal Neural Cultures. Primary hip-
pocampal neurons and glia from 5-day-old mouse pups
(C57BL6; background of both the FORKO and APPsw/
PS1
￿9) were isolated, mechanically and enzymatically dis-
sociated, counted and seeded (5 × 104 cells/well) onto col-
lagen-coated glass coverslips, and grown in a 24-well cell
culture plate (Corning) at 37◦Ca n d5 %C O 2 initially in phe-
nol-free Dulbecco’s Modiﬁed Eagle’s Medium (Invitrogen)
with 1mM L-Glutamine (Sigma), sodium pyruvate, and
penicillin-streptomycin-neomycin antibiotic cocktail (In-
vitrogen). On the second day in vitro, cells are cultured
in Neurobasal A medium without phenol red (Invitrogen)
supplemented with 2% (v/v) B-27 supplement (Invitrogen),
1% (v/v) penicillin-streptomycin-neomycin PSN (Invitro-
gen), and 1mM L-Glutamine (Sigma). Cells were treated on
day 5 in vitro with letrozole (1μM) for 24hrs.
2.6. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl Tetrazolium
Bromide (MTT) Assay. After various time intervals, 50ul
of phosphate buﬀer saline (PBS; pH 7.2) containing MTT
(5mg/mL) was added to each well, resulting in a ﬁnal MTT
concentration of 0.5mg/mL. Cells were incubated at 37◦C
with 5% CO2 and >95% relative humidity for 180min, after
which media was removed. DMSO was added to lyse the
cells and dissolve the formazan produced. Triplicates from
each well were collected into a 96-well plate (Sarstedt) and
the absorbance at 595nm of each well was measured using
a Benchmark microplate reader (Bio-Rad, Mississauga, ON,
Canada). Data was tabulated and graphed using Microsoft
Excel 2007.
2.7. Immunocytochemistry. Following treatment, cells were
ﬁxed in 4% paraformaldehyde for 15min at room tem-
perature (RT), followed by three washes for 5min each
with phosphate buﬀer saline (PBS, pH 7.2); the samples
were permeabilized with 0.1% triton-X-100 at RT for 5min,
followed again by three washes in PBS. Nonspeciﬁc binding
sites were blocked for 60 min at RT with 10% goat serum4 Journal of Aging Research
(Sigma) diluted in PBS. The samples were then incubated
o v e r n i g h ta t4 ◦C with the primary antibodies (Rat anti-
macII, 1:500 gift from collaborator; rabbit anti-GFAP,
1:250, DakoCytomation; mouse anti-βIII-tubulin, 1:100,
Chemicon). Following the incubation, samples were washed
three times in PBS and incubated for 60min at RT with the
secondary antibodies (antirat Rhodamine red, 1:500, Jack-
son Laboratories; antirabbit AlexaFluor594, 1:1000, Molec-
ular Probes; antimouse AlexaFluor 594, 1:1000, Molecular
Probes). Following three rinses in PBS, the samples were
counterstained with Hoechst 33258 (Molecular Probes),
rinsed once with distilled water, and mounted onto glass
slides using Aqua-Poly/Mount (Polysciences). Fluorescence
images were acquired at 63x with a Leica DFC350FX
monochrome digitalcameraconnectedtoaLeicaDMI4000B
inverted ﬂuorescence microscope. Images were acquired and
pseudocolored using Leica ApplicationSuite (LAS) software.
2.8.StatisticalAnalysis. AlldatawereexpressedasmeanSEM
and analyzed by one-way ANOVA. When a signiﬁcant eﬀect
wasobtainedwithone-wayANOVA,student’st-testwasused
for analyzing the signiﬁcance of the diﬀerence between two
means. To test for interactions between genotype and gender
foreach behavioralparadigm, two-way factorial ANOVAwas
employed. A P value < 0.05 was considered to be statistically
signiﬁcant, unless stated otherwise.
3.Results
3.1. Generation of the Mouse Model FORKO-APPsw/PS1
￿9.
To analyze the impact of reduced estrogens on AD devel-
opment, we generated mice carrying the APPsw and PS1
￿9
transgenes in either a wild type or FORKO background
(Figure 1).Forthis, doubletransgenic APPsw/PS1Δ9 females
exhibiting increased production of both Aβ40/42 peptides
[40] were crossed with FORKO males [3]. In all the mice
analyzed, the transgenes were kept at the heterozygote level
to avoid any phenotype related to their insertion site in the
genome. In view of the sterility of FORKO females, the high
incidence of lost litters, and the need to select for alleles
of three loci, a large number of crossings were required
over three generations, representing four years of work, to
obtain suﬃcient mice for the present study (see section
2). The FORKO-APPsw/PS1
￿9 mice did not show marked
phenotypic diﬀerences from the parental lines, FORKO or
APPsw/PS1
￿9, up to at least 6 months of age.
3.2. Analysis of Amyloid Plaque Deposits in APPsw/PS1
￿9and
FORKO-APPsw/PS1
￿9M i c e .Mouse models with varying
APP mutations have not shown very extensive amyloid
aggregation before 18 months of age [39, 40]. Studies of the
double transgenic APPsw/PS1
￿9 mice provided evidence
for elevated Aβ-levels in 6-month-old mice, but extensive
extracellular Aβ-deposits in the cortex and hippocampus
were described in 9–12-month-old mice [40]. We focused
on 6-month-old mice, as this period corresponds to an early
stage in disease development. The nature of deposits in
APPsw/PS1
￿9m i c ea n dt h eF O R K O - A P P s w / P S 1
￿9m i c e
was assessed by staining sagital sections with a rabbit poly-
clonal antibody FCA18, which recognizes both Aβ40 and
Aβ42 [45], as well as with Aβ40 (CT40)- and Aβ42 (CT42)-
speciﬁc antibodies (Figure 2(a)). There was no signiﬁcant
diﬀerence in the number of plaques revealed by the FCA18,
CT40, or CT42 antibodies, as seen by the quantiﬁcation
in Figure 2(a). However, upon careful examination of the
plaques using FCA18 antibodies we noted a marked diﬀer-
ence in sizes and compactness (or density) of the immuno-
positive plaques (Figure 2(b) and Supplementary Figure 1
in Supplementary Material available online at doi: 10.4061/
2011/251517). Both mouse strains have a large number of
Aβ-aggregates in the frontal association cortex (Figure 2(b),
(A) and (B)), as well as in the medial and lateral parietal
sensory cortex (Figure 2(b), (C) and (D)) and the hippo-
campus (Figure 2(b), (E) and (F)). However, the perimeters
of the plaques found in the brains of FORKO-APPsw/PS1
￿9
are signiﬁcantly larger and less dense, as revealed by the
staining pattern, in comparison with APPsw/PS1
￿9t r a n s -
genic mice, concurring with observations from Borchelt
et al. [40]. Quantitative data regarding the image analyses
of immunoreactive plaques are presented in pie charts and
clearly show plaques in cortical regions with larger perime-
ters (17% of plaques >200um) in FORKO-APPsw/PS1
￿9
than in APPsw/PS1
￿9 littermates (2% of plaques >200um).
These diﬀerences were not noticeable at 3 months of age
given the relatively sparse deposition of plaques in both
transgenic mouse strains (data not shown).
Aside from the brain regions in which plaque formation
was commonly detected (i.e., cortex and hippocampus) in
the APPsw/PS1
￿9a n dF O R K O - A P P s w / P S 1
￿9m i c e ,a m y -
loid deposits develop in the olfactory bulb and occipital lobe
(Supplementary Figure 2). Interestingly, even subcortical
areas like the cerebellum, a brain region mainly considered
to be devoid of Aβ-aggregates in most other animal models
[46],hadalownumberofsmall size plaques(Supplementary
Figure 2, (i)–(l)).
3.3. Astrocyte Hypertrophy and Microglial Activation. Im-
munostaining with antibodies against GFAP and Iba1/Mac
II was used to assess the morphology of astrocytes and
microglia in FORKO-APPsw/PS1
￿9a n di nA P P s w / P S 1
￿9.
At 6 months of age, there were no marked diﬀerences be-
tween the two genotypes: (i) GFAP-positive astroglia were
enlarged and abundant in FORKO-APPsw/PS1
￿9m i c ea n d
in APPsw/PS1
￿9m i c e( Figure 3), and (ii) Iba1/MacII-posi-
tivemicrogliawerealsoenlargedandexhibitedmorphologies
reminiscent of highly activated states. Diﬀerences between
the strains at 3 months of age were not apparent either
(Figures 3(a), (A) and (B) and 3(b), (A) and (B)).
Multiple attempts to set primary neural cortical and hip-
pocampal cultures from FORKO-APPsw/PS1
￿9m i c ef a i l e d
because the cells from these chimeric mice detached within
24–30 hours, whereas the same conditions were suitable for
control cultures with similar genetic background (C57BL6).
Interestingly, while performing brain dissection for primary
cultures,thebrainsofchimericmiceappearedlessstructured
and less solid suggesting that connections between neuralJournal of Aging Research 5
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Figure 2: Six-month-old sex-hormone-imbalanced FORKO-APPsw/PS1
￿9 mice show similar plaque localization and number but dif-
ference in plaque appearance and size compared to mice coexpressing APPsw/PS1
￿9 alone. (a) Six-month-old sex-hormone-imbalanced
FORKO-APPsw/PS1
￿9 mice show no signiﬁcant changes in plaques number compared to mice coexpressing APPsw/PS1
￿9a l o n e .
APPsw/PS1
￿9 and FORKO-APPsw/PS1
￿9 mice were examined by immunocytochemical staining for Aβ peptide with the polyclonal
antibody anti-Aβ40/42 (FCA18), anti-Aβ40 (CT40), or anti-Aβ42 (CT42). Quantiﬁcation of plaques number was achieved by plaque
counting on sagittalbrain sections of hippocampus and cortex in APPsw/PS1Δ9(+/+; n = 6) and FORKO-APPsw/PS1
￿9( −/−; n = 6). (b)
Presented is anti-Aβ40/42 (FCA18) immunostainingof sagittal brain sections from APPsw/PS1
￿9( n = 6; (A), (C), and (E)) and FORKO-
APPsw/PS1Δ9( n = 6; (B), (D), and (F)). By 6 months of age, both mice strains had developed Aβ plaques in typical areas of the brain,
such as ((A) and (B)) the frontal cortex, ((C) and (D)) the parietal cortex, and ((E) and (F)) the hippocampus. Note that many more
relatively large and diﬀuse plaques are found in chimeric mice compared to those in APPsw/PS1
￿9 brains. Scale bar in all panels is 20um.
((G) and (H)) Quantiﬁcation of the plaques perimeter revealed 16.67 % of large, 17.54 % of medium, and 65.79 % of small plaques in
FORKO-APPsw/PS1
￿9(H) compared to 2.3 % of large plaques, 14.94 % of medium and 82.76% of smallplaques in APPsw/PS1
￿9(G).6 Journal of Aging Research
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Figure 3: Sex-hormone-imbalanced 6-month-old FORKO-APPsw/PS1
￿9 mice show enhanced number and hypertrophy of astrocytes and
microglia in the vicinity of plaques in the hippocampus. Immunostaining for astrocytes and microglia was performed in representative
areas of the cortex using polyclonal antibodies for GFAP (a) and MacII in (b) in APPsw/PS1
￿9 mice and FORKO-APPsw/PS1
￿9.Note that
astroglia and microglia show an enlargement and increase in number, suggesting glial activation and inﬂammation in both APPsw/PS1
￿9
FORKO-APPsw/PS1
￿9 mice, more strikingly in the latter model. Scale bar measures 50μm.Journal of Aging Research 7
cells were reduced in these brains. Therefore, we used pri-
mary hippocampal dispersed cultures from wild-type mice
and exposed them to letrozole, an aromatase inhibitor, for
24hrs to assess the changes in the neural cells with sup-
pressed estrogen synthesis. Hippocampal neural cells treated
with 10−6 M letrozole stably attached to the plastic surface,
exhibiting similar viability to control cultures (Supplemen-
tary Figure 3). Morphological changes in glial state and
neurons in this in vitro model are shown (Figures 4(a) and
4(b)). BIII-tubulin-positive letrozole-treated neurons exhib-
ited signiﬁcant enlargement of their processes compared to
the control (Figure 4(a), (A) and (B)), while highly activated
microglia showed increased immunoreactivity for mac-2
following letrozole treatment (Figure 4(a),( E )a n d( F ) )a n d
GFAP-immunopositive astrocytes were signiﬁcantly larger
in letrozole treated cells compared with untreated controls
(Figure 4(a), (C) and (D)), as conﬁrmed by quantitative
analysis (Figure 4(b)).
Given thatmetabolic dysfunction and oxidative stress are
early events in AD [33, 47, 48] and that many of the neuro-
protective eﬀects of estrogens have been attributed to rescue
ofmitochondrial function [49]we also decidedto investigate
mitochondrial status following estrogen deprivation. In
primary hippocampal neural cultures with and without
letrozoletreatment for24hrs, welabeledmitochondria using
MitoTracker Deep Red 633 (Figure 4 G-H). Images captured
with confocal microscopy reveal signiﬁcant mitochondrial
fragmentation and loss following letrozole treatment, which
hasbeenshowntocorrelatewithastateofmitochondrialand
synaptic dysfunction in the CNS [50].
4.Discussion
Estrogens in the CNS play both neuroprotective and neu-
romodulatory roles [51–53], which was associated with the
increased incidence of age-related neurodegenerative dis-
eases in women [54, 55]. The controversies over the con-
centrations of peripheral and brain sex hormones in cases
with mild cognitive impairments (MCI) and AD are still not
resolved [15, 17, 56–58]. Several clinical trials are ongoing
and the results conﬁrming or refuting the role of declining
endogenous estradiol and eﬀectiveness of hormone replace-
ment therapy in early or even undiagnosed AD are eagerly
awaited.
Resultsfromourstudiespresentanewmousemodelwith
three mutated loci (FORKO-APPsw/PS1Δ9), conferring sex
hormone imbalance and AD pathology. The results clearly
show that FORKO-APPsw/PS1
￿9mic eha v elar gerandmor e
diﬀuseplaquesthanthedoubletransgenicmodel,inaddition
to signiﬁcant hypertrophy and activation of microglia and
astrocytes, corroborating ﬁndings that estrogens are potent
glia regulators [17, 22, 59, 60] whose state may be either
beneﬁcial or destructive in the CNS [61], particularly in
aging.
FORKO females exhibit hypergonadotropic-hypogonad-
ism with high levels of circulating FSH and LH similar to
the postmenopausal state in women [62]. In menopause,
dramaticandrapidlyoccurringcessationofgonadalfunction
leads to a loss of estrogens in women around 51 years of age
[44, 63]. In contrast to menopause in women, men do not
experience irreversible arrest of reproductive capacity in old
age and aging in men is characterized by a gradual and slow
decline in testosterone with half bioavailable testosterone
levels at 75 years of age relative to younger men [64, 65].
Consequent to gender diﬀerences in senescence, signiﬁcant
diﬀerences are also found in the incidence, timing, and sus-
ceptibility of age-related conditions, such as osteoporosis,
obesity, cardiovascular diseases, type 2 diabetes, depression,
anxiety, insomnia, and memory impairment [44, 63, 64, 66–
76].
Results from the triple mutant mouse model FORKO/
APPsw/PS1
￿9 presented here support the notion that the
reduced circulating levels of estradiol do not signiﬁcantly
contribute to the plaque numbers but rather inﬂuence their
compactness and size. Moreover, subphysiological concen-
trations of estrogens in this mouse model of Alzheimer’s
disease (FORKO/APPsw/PS1
￿9) show signiﬁcant reactivity
of both astrocytes and microglia.
Bothgliaandneuronscansynthesize estrogensinhuman
and rodent brains. The synthesis is catalyzed by the enzyme
aromatase, widely distributed in the brain regions including
those aﬀected in AD, for example, basal forebrain, cere-
bral cortex, and hippocampus [1]. Although the positron
emission tomography of human subjects has given us some
insight into the general map of the human aromatase ex-
pression, the detailed distribution map still remains to be
completed. Several studies point towards the signiﬁcance of
the local production of estradiol by aromatase conversion
of testosterone in the brain, particularly on the neurons
in the hippocampus [1, 16, 20, 77, 78]. Moreover, estro-
gens exert inhibitory eﬀects on inﬂammation as well as,
microglial and astroglial activation in several brain regions
including cerebral cortex and hippocampus [22, 26, 59, 60,
79, 80]. Speciﬁcally, estrogen downregulates the release of
inducible nitric oxide synthase (iNOS), tumour necrosis
factor alpha (TNFα), interleukin-6 (IL-6), and interferon-
gamma inducible protein-10 (IP-10) in cultured astrocytes
activated with lipopolysaccharide (LPS) [81, 82]. Moreover,
it was shown previously that long-term estrogen deprivation
accelerates the appearance of highly reactive microglia at
amyloid deposits, an event that was prevented by estradiol
replacement [22].
The link between inﬂammation, microglia, and AD pa-
thologywasproposedlongago[34],butstudiesinvestigating
the origin of microglia associated with plaques in AD are
more recent and bring out diﬀerent observations [83–85].
Microglia are attracted to the region surrounding senile
plaques in human and rodent tissues [86–92]a n dA β40
and Aβ42 isoforms serve as chemoattractants. Conversely,
chronic inﬂammation of the central nervous system asso-
ciated with hyperactive states of glial cells is a risk factor
for AD. We did not explore the origin of microglia but we
show that they play a role in determining the size and shape
of plaques in both APPsw/PS1
￿9 mice and in the FORKO-
APPsw/PS1
￿9 mice. Importantly, this diﬀuse plaque state
created by activated microglia unable to eﬃciently clear Aβ
aggregatesmayleadtothereleaseofsolubleformsofAβfrom8 Journal of Aging Research
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Figure 4: Immunocytochemical assessment of neuronal and glial status in primary hippocampal cultures treated with letrozole. Primary
dissociated hippocampal cultures were treated with letrozole (1μM, 24hrs), following which immunocytochemical analysis was performed
for cell-speciﬁc markers. (a) Neurons ((A) and (B)) were stained with antibodies against beta III tubulin (1:100), astrocytes ((C) and (D))
with anti-GFAP (1:500), and microglia ((E) and (F)) with anti-Mac-2 (1:350). Note the marked astrocyte hypertrophy in letrozole-treated
cells. Arrowheads indicate enlargement of the neuronal processes following Lz treatment. Arrows in (F) outline activated microglia, which
exhibit increased mac-2 staining. ((G) and (H)) MitoTracker Deep Red 633 staining revealed truncated mitochondria in Lz-treated cells
compared with control, indicative of increased mitochondrial ﬁssion and potentially mitochondrial dysfunction. Scale bar (20μm) in ﬁrst
panel is representative for all panels. (b) Quantiﬁcation of stained area per cell for neurons (βIII-tubulin), astrocytes (GFAP), and microglia
(mac-2) following letrozole treatment.
theseplaques,which wouldthereforeactasreservoirs,assug-
gested by others [93]. Recent studies by Selkoe suggest that
amyloid ﬁbrils from plaques are not as deleterious as soluble
Aβ, particularly in its dimeric form [94, 95]. Inﬂammation
in AD and speciﬁcally the eﬀects on microglial activation
in relation to Aβ removal are controversial: some claim it
as a self-reinforcing positive feedback loop that potentiates
the damaging eﬀects of Aβ, while others claim that activated
microglia are neuroprotective [96, 97].
Toaddress thequestionofastrocyte hypertrophy and mi-
croglia activation in states of reduced estradiol synthesis by
neural cells, we performed experiments with primary cul-
tures. Dispersed primary hippocampal and cortical cultures
from the brains of FORKO-APPsw/PS1Δ9 were not viable,
therefore, for in vitro studies, we used wild-type mice and
a common pharmacological approach to reduce estradiol
synthesis using letrozole which inhibits aromatase enzymatic
activity [16, 77]. Primary dissociated hippocampal culturesJournal of Aging Research 9
treated with letrozole show marked glial hypertrophy and
microglial activation suggesting that such cultures could be
useful for screening new therapies for neurological disorders
accompanied by gliopathies in hypoestrogenic states. Our
results show mac-2-positive staining in the hippocampus
of chimeric mice, a marker of activated microglia, which
is in accordance with the observation of mac-2 upregula-
tion in wild-type cultures with pharmacologically inhibited
aromatase by letrozole, previously used to study synaptic
plasticity in hippocampal primary cultures [16, 77, 78, 98].
This experimental paradigm also allowed an assessment of
mitochondrialmorphologicalandfunctionalstatusinneural
cells, given that mitochondria respond to estradiol treatment
[49].
Mitochondria are organelles known to be aﬀected in AD
[99]. It was reported that impairments in mitochondrial
ﬁssion and fusion can lead tomitochondrial dysfunction and
synaptic deﬁcits in AD [100, 101]. Estradiol acts through
mitochondria to exhibit neuroprotection. Our ﬁnding that
estradiol deprivation leads to mitochondrial fragmentation
and loss is not surprising, but it is among the ﬁrst to show a
correlation between glial activation and mitochondrial frag-
mentationinstatesofestr ogendepri vationandsex-hormone
imbalance. These observations suggest that estrogen may
modulate mitochondria to regulate glial cell activation and
hypertrophy.
In summary, results from the present study support the
notion that activated glia in a hypoestrogenic state could
potentiatetheeﬀectsofinﬂammation, inadditiontoenhanc-
ing Aβ release from plaques, and Aβ oligomerization. These
forms of Aβ are major soluble neurotoxicants [102], there-
fore it is plausible that in the aged chimeric brains, cell
loss could be due to enhanced oligomer formation. Results
from the pilot studies indicate that the levels of Aβ in
the brain of chimeric mice are not signiﬁcantly diﬀerent
from APPsw/PS1
￿9, but the kinetics of Aβ monomer and
soluble oligomer formation remains to be determined. In
order to detect and quantify small diﬀerences between these
two genotypes with limited CSF and blood samples, we are
currently developing nanobased sensors which could enable
measurements of Aβ monomers and oligomers in small
volumes of these biological samples.
In addition, results from our chimeric FORKO/APPsw/
PS1
￿9 mouse model are in line with both the Brinton hypo-
thesis [103, 104] and the critical window hypothesis [105].
Although the two interrelated hypotheses, for example, (1)
healthy cell bias of gonadal hormone action hypothesis
[103, 104] and (2) the critical window hypothesis [105],
reconcile previous controversies, they do not yet explain the
positive versus negative eﬀects of estrogens on cognition.
Ongoing clinical studies with initiated estrogen therapy in
young women, together with mechanistic investigations, will
provide new insights to resolve the controversial issues. Our
studies are also in line with elegant work by Garcia-Segura’s
group suggesting that the brain aromatase in the central
nervous system and the local production of estradiol in the
brain play a critical role in maintaining normal physiological
centralnervous system functions, includingthose in neurons
andglialcellsaﬀectedinAD[59,79].Aparticularlyattractive
feature of future studies is to explore the selective estrogen
receptor modulators to normalize hyperactive glial cells and
the release of proinﬂammatory cytokines and chemokines in
inﬂammation, not only in AD, but also in other neurological
disorders accompanied by excessive gliosis [80].
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